Crescent Biopharma (NASDAQ:CBIO) Stock Jumps 5.2% - Here's Why

Key Points

• Crescent Biopharma shares rose 5.2% to $15.29 in midday trading, though volume was 84% below the stock’s average session volume.
• Analyst sentiment is mixed but leans positive: the stock has a “Moderate Buy” consensus rating and a $29.60 average price target, including recent upgrades from TD Cowen and Wedbush.
• The company remains unprofitable, reporting a quarterly loss of $0.74 per share, while insiders sold shares under pre-arranged plans to cover tax obligations; institutional investors own approximately 75.19% of the stock.

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) shares traded up 5.2% during mid-day trading on Tuesday. The stock traded as high as $15.62 and last traded at $15.29. 48,835 shares traded hands during trading, a decline of 84% from the average session volume of 296,451 shares. The stock had previously closed at $14.53.

Analyst Ratings Changes

A number of research firms recently issued reports on CBIO. HC Wainwright reiterated a "neutral" rating on shares of Crescent Biopharma in a report on Thursday, July 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Crescent Biopharma in a research note on Friday, August 7th. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a report on Monday, August 24th. Finally, Wedbush reaffirmed an "outperform" rating and set a $27.00 price objective on shares of Crescent Biopharma in a report on Monday, September 14th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.60.

Crescent Biopharma Trading Down 1.1%

The firm's 50 day simple moving average is $17.08 and its 200-day simple moving average is $17.60. The company has a market capitalization of $533.89 million, a price-to-earnings ratio of -2.14 and a beta of 1.24.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, meeting analysts' consensus estimates of ($0.74). As a group, sell-side analysts forecast that Crescent Biopharma, Inc. will post -2.93 EPS for the current fiscal year.

Insider Transactions at Crescent Biopharma

In related news, COO Jonathan McNeill sold 3,839 shares of the firm's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.71, for a total value of $64,149.69. Following the completion of the sale, the chief operating officer owned 134,588 shares in the company, valued at $2,248,965.48. This trade represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Joshua Brumm sold 7,837 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.71, for a total transaction of $130,956.27. Following the completion of the transaction, the chief executive officer directly owned 271,765 shares of the company's stock, valued at approximately $4,541,193.15. This trade represents a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,726 shares of company stock valued at $285,501 in the last quarter. Insiders own 24.84% of the company's stock.

Institutional Investors Weigh In On Crescent Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in CBIO. Legal & General Group Plc acquired a new stake in shares of Crescent Biopharma in the second quarter valued at approximately $38,000. Cannon Global Investment Management LLC purchased a new stake in Crescent Biopharma in the first quarter valued at approximately $187,000. Persistent Asset Partners Ltd acquired a new stake in shares of Crescent Biopharma during the 2nd quarter worth $197,000. Wellington Management Group LLP acquired a new stake in Crescent Biopharma during the second quarter worth about $263,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Crescent Biopharma during the 2nd quarter worth approximately $320,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc NASDAQ: CBIO is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company's activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.